| Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences | 09/03 07:30 | globenewswire.com |
| Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease | 08/22 07:31 | globenewswire.com |
| Cognition Therapeutics, Inc. (CGTX) Q1 2024 Earnings Call Transcript | 08/11 00:55 | seekingalpha.com |
| Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update | 08/08 07:00 | globenewswire.com |
| Cognition Therapeutics to Report Second Quarter 2024 Financial Results | 08/05 07:30 | globenewswire.com |
| Why Is Cognition Therapeutics (CGTX) Stock Down 33% Today? | 07/29 11:09 | investorplace.com |
| Cognition Therapeutics' Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer's Patients | 07/29 07:00 | globenewswire.com |
| Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at 8:30am ET on Monday July 29, 2024 | 07/26 16:11 | globenewswire.com |
| Results from Cognition Therapeutics' Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease Accepted for Presentation at AAIC | 07/02 07:30 | globenewswire.com |
| Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease | 05/21 07:30 | globenewswire.com |